Brokerages forecast that Amedisys Inc (NASDAQ:AMED) will post $0.85 earnings per share for the current quarter, according to Zacks. Six analysts have made estimates for Amedisys’ earnings, with the lowest EPS estimate coming in at $0.82 and the highest estimate coming in at $0.89. Amedisys reported earnings of $0.56 per share in the same quarter last year, which would indicate a positive year over year growth rate of 51.8%. The company is expected to issue its next earnings results after the market closes on Wednesday, February 27th.
According to Zacks, analysts expect that Amedisys will report full-year earnings of $3.58 per share for the current year, with EPS estimates ranging from $3.55 to $3.62. For the next financial year, analysts expect that the firm will post earnings of $4.04 per share, with EPS estimates ranging from $3.97 to $4.25. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Amedisys.
Several equities research analysts recently commented on AMED shares. BidaskClub cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Craig Hallum cut shares of Amedisys from a “buy” rating to a “hold” rating and cut their price objective for the company from $116.00 to $104.00 in a research report on Friday, October 26th. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Monday, January 21st. UBS Group started coverage on shares of Amedisys in a research report on Friday, November 16th. They issued a “neutral” rating and a $126.00 price objective on the stock. Finally, Benchmark raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price objective on the stock in a research report on Tuesday, October 30th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $114.62.
Shares of NASDAQ AMED traded down $3.76 during midday trading on Friday, reaching $130.35. 270,359 shares of the stock were exchanged, compared to its average volume of 293,030. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 58.98, a P/E/G ratio of 1.77 and a beta of 1.43. Amedisys has a 12 month low of $54.06 and a 12 month high of $140.91. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12.
In other Amedisys news, insider David B. Pearce sold 398 shares of the business’s stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $119.25, for a total transaction of $47,461.50. Following the sale, the insider now directly owns 11,420 shares of the company’s stock, valued at approximately $1,361,835. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider David B. Pearce sold 410 shares of the business’s stock in a transaction dated Monday, December 24th. The stock was sold at an average price of $106.61, for a total transaction of $43,710.10. Following the sale, the insider now directly owns 11,010 shares in the company, valued at $1,173,776.10. The disclosure for this sale can be found here. Insiders have sold a total of 22,856 shares of company stock worth $2,754,785 over the last three months. Insiders own 2.60% of the company’s stock.
Large investors have recently modified their holdings of the business. First Hawaiian Bank lifted its position in Amedisys by 45.6% during the 4th quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after buying an additional 130 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in Amedisys during the 4th quarter worth about $50,000. Meeder Asset Management Inc. lifted its position in Amedisys by 107.4% during the 4th quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock worth $56,000 after buying an additional 247 shares in the last quarter. Group One Trading L.P. bought a new stake in Amedisys during the 4th quarter worth about $90,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after purchasing an additional 2,172 shares during the last quarter. 92.49% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Story: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.